October 2025
1. LIN JK, Niu J, Giordano SH, Li P, et al
   Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancers.
   J Clin Oncol. 2025;43:3254-3265.
   

   >> Share

   
   
2. CHEN L, Wang Y, Cai C, Ding Y, et al
   Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.
   J Clin Oncol. 2025 Oct 2:JCO2502281. doi: 10.1200/JCO-25-02281.
   

   >> Share

   
   September 2025
3. BEITER ER, Patel SR, Chen CT
   Immunotherapy Efficacy in Mismatch Repair-Proficient Colorectal Cancer Patients With and Without Liver Metastases.
   J Clin Oncol. 2025 Sep 11:JCO2501044. doi: 10.1200/JCO-25-01044.
   

   >> Share

   
   
4. GERMANI MM, Borelli B, Hashimoto T, Nakamura Y, et al
   Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials.
   J Clin Oncol. 2025 Sep 4:JCO2501003. doi: 10.1200/JCO-25-01003.
   

   >> Share

   
   July 2025
5. WANKHEDE D, Halama N, Kloor M, Brenner H, et al
   Diabetes and Colorectal Cancer Risk and Survival According to Tumor Immunity Status.
   J Clin Oncol. 2025 Jul 14:JCO2500148. doi: 10.1200/JCO-25-00148.
   

   >> Share

   
   June 2025
6. ASSENAT E, Ben Abdelghani M, Gourgou S, Perrier H, et al
   Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial.
   J Clin Oncol. 2025 Jun 20:JCO2402754. doi: 10.1200/JCO-24-02754.
   

   >> Share

   
   May 2025
7. SHAH P, Philip T
   They Not Like Us: Evaluating the Diverse Strategies in Locally Advanced Rectal Cancer Treatment.
   J Clin Oncol. 2025;43:1620-1624.
   

   >> Share

   
   
8. BACHET JB, de Gramont A, Raeisi M, Rakez M, et al
   Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancerologie Digestive Database.
   J Clin Oncol. 2025 May 5:JCO2401968. doi: 10.1200/JCO-24-01968.
   

   >> Share

   
   
9. VEENSTRA CM, Abrahamse P, Hamilton AS, Ward KC, et al
   Breast, Colorectal, and Pancreatic Cancer Mortality With Pathogenic Variants in ATM, CHEK2, or PALB2.
   J Clin Oncol. 2025;43:1587-1596.
   

   >> Share

   
   April 2025
10. ROUSSEAU B, Cercek A
    Entering the Era of Multidimensional Prognostication for Personalized Risk Assessment in Stage III Colon Cancer.
    J Clin Oncol. 2025 Apr 11:JCO2500205. doi: 10.1200/JCO-25-00205.
    

    >> Share

    
    
11. PIETRANTONIO F, Salvatore L, Esaki T, Modest DP, et al
    Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer.
    J Clin Oncol. 2025 Apr 11:JCO2402026. doi: 10.1200/JCO-24-02026.
    

    >> Share

    
    February 2025
12. ZHANG J, Chi P, Shi L, Cui L, et al
    Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years.
    J Clin Oncol. 2025;43:633-640.
    

    >> Share

    
    
13. WIDMAR M, McCain M, Mishra Meza A, Ternent C, et al
    Cost-Effectiveness of Total Neoadjuvant Therapy With Selective Nonoperative Management for Locally Advanced Rectal Cancer: Analysis of Data From the Organ Preservation for Rectal Adenocarcinoma Trial.
    J Clin Oncol. 2025;43:672-681.
    

    >> Share

    
    
14. MORRIS VK, Kennedy EB, Amin MA, Aranha O, et al
    Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline.
    J Clin Oncol. 2025;43:605-615.
    

    >> Share

    
    
15. TAIEB J, Souglakos J, Boukovinas I, Falcoz A, et al
    Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials.
    J Clin Oncol. 2025 Feb 4:JCO2400648. doi: 10.1200/JCO.24.00648.
    

    >> Share

    
    
16. STINTZING S, Klein-Scory S, Fischer von Weikersthal L, Fuchs M, et al
    Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study.
    J Clin Oncol. 2025 Feb 4:JCO2401174. doi: 10.1200/JCO.24.01174.
    

    >> Share

    
    January 2025
17. GALLOIS C, Sroussi M, Andre T, Mouillet-Richard S, et al
    Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials.
    J Clin Oncol. 2025 Jan 31:JCO2302262. doi: 10.1200/JCO.23.02262.
    

    >> Share

    
    
18. OULADAN S, Orouji E
    Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy.
    J Clin Oncol. 2025 Jan 13:JCO2402081. doi: 10.1200/JCO-24-02081.
    

    >> Share

    
    
19. RAGHAV KPS, Guthrie KA, Tan B Jr, Denlinger CS, et al
    Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial.
    J Clin Oncol. 2025 Jan 6:JCO2401710. doi: 10.1200/JCO-24-01710.
    

    >> Share

    
    November 2024
20. AVALLONE A, Giuliani F, De Stefano A, Santabarbara G, et al
    Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial.
    J Clin Oncol. 2024 Nov 22:JCO2400979. doi: 10.1200/JCO.24.00979.
    

    >> Share

    
    
21. 
    Erratum: Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.
    J Clin Oncol. 2024 Nov 19:JCO2402458. doi: 10.1200/JCO-24-02458.
    

    >> Share

    
    October 2024
22. AHN DH, Ridinger M, Cannon TL, Mendelsohn L, et al
    Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.
    J Clin Oncol. 2024 Oct 30:JCO2401266. doi: 10.1200/JCO-24-01266.
    

    >> Share

    
    
23. SCOTT AJ, Kennedy EB, Berlin J, Brown G, et al
    Management of Locally Advanced Rectal Cancer: ASCO Guideline.
    J Clin Oncol. 2024;42:3355-3375.
    

    >> Share

    
    
24. XIA F, Wang Y, Wang H, Shen L, et al
    Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH).
    J Clin Oncol. 2024;42:3308-3318.
    

    >> Share

    
    September 2024
25. CHIBAUDEL B, Raeisi M, Cohen R, Yothers G, et al
    Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis.
    J Clin Oncol. 2024 Sep 4:JCO2400394. doi: 10.1200/JCO.24.00394.
    

    >> Share

    
    August 2024
26. LU J, Xing J, Zang L, Zhang C, et al
    Extent of Lymphadenectomy for Surgical Management of Right-Sided Colon Cancer: The Randomized Phase III RELARC Trial.
    J Clin Oncol. 2024 Aug 27:JCO2400393. doi: 10.1200/JCO.24.00393.
    

    >> Share

    
    
27. TAKASHIMA A, Hamaguchi T, Mizusawa J, Nagashima F, et al
    Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018).
    J Clin Oncol. 2024 Aug 26:JCO2302722. doi: 10.1200/JCO.23.02722.
    

    >> Share

    
    July 2024
28. WILLIAMS CJM, Gray R, Hills RK, Shires M, et al
    Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial.
    J Clin Oncol. 2024 Jul 31:JCO2302030. doi: 10.1200/JCO.23.02030.
    

    >> Share

    
    
29. SARTORE-BIANCHI A, Marsoni S, Amatu A, Torri V, et al
    How to Test HER2 for Predicting Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer? Evidence From the Secondary Analysis of Biomarkers of CALGB/SWOG 80405.
    J Clin Oncol. 2024 Jul 30:JCO2400805. doi: 10.1200/JCO.24.00805.
    

    >> Share

    
    
30. PENG C, Kircher SM
    Neoadjuvant Chemotherapy in Colon Cancer: More Than Just an Optical Illusion.
    J Clin Oncol. 2024 Jul 25:JCO2400220. doi: 10.1200/JCO.24.00220.
    

    >> Share

    
    
31. QIU YY, Yang S, Sun MQ, Huang JH, et al
    Age May Be an Important Factor Affecting Neoadjuvant Chemotherapy in Patients With Locally Advanced Colon Cancer.
    J Clin Oncol. 2024 Jul 24:JCO2400883. doi: 10.1200/JCO.24.00883.
    

    >> Share

    
    
32. KAPADIA P, Zimolzak AJ, Upadhyay DK, Korukonda S, et al
    Development and Implementation of a Digital Quality Measure of Emergency Cancer Diagnosis.
    J Clin Oncol. 2024;42:2506-2515.
    

    >> Share

    
    
33. CHLEBOWSKI RT, Aragaki AK, Pan K, Luo J, et al
    Estrogen Plus Progestin and Colorectal Cancer: Long-Term Findings From the Women's Health Initiative Randomized Clinical Trial.
    J Clin Oncol. 2024 Jul 19:JCO2302092. doi: 10.1200/JCO.23.02092.
    

    >> Share

    
    
34. JAIN A, Lau NS
    Liver Transplantation in Colorectal Cancer With Unresectable Liver Metastases: Disease Biology Cannot Be Ignored.
    J Clin Oncol. 2024 Jul 8:JCO2400619. doi: 10.1200/JCO.24.00619.
    

    >> Share

    
    June 2024
35. NOWAK JA, Twombly T, Ma C, Shi Q, et al
    Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).
    J Clin Oncol. 2024 Jun 18:JCO2301680. doi: 10.1200/JCO.23.01680.
    

    >> Share

    
    
36. ANTONIOTTI C, Rossini D, Pietrantonio F, Salvatore L, et al
    Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study.
    J Clin Oncol. 2024 Jun 12:JCO2302728. doi: 10.1200/JCO.23.02728.
    

    >> Share

    
    
37. KAWAZOE A, Xu RH, Garcia-Alfonso P, Passhak M, et al
    Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.
    J Clin Oncol. 2024 Jun 4:JCO2302736. doi: 10.1200/JCO.23.02736.
    

    >> Share

    
    
38. BUTT J, Epplein M
    Potent Tool: Helicobacter pylori Treatment to Reduce the Risk of Both Gastric and Colorectal Cancers.
    J Clin Oncol. 2024;42:1865-1867.
    

    >> Share

    
    May 2024
39. 
    Erratum: Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial.
    J Clin Oncol. 2024 May 22:JCO2400997. doi: 10.1200/JCO.24.00997.
    

    >> Share

    
    April 2024
40. 
    Erratum: Predicting Functional Recovery and Quality of Life in Older Patients Undergoing Colorectal Cancer Surgery: Real-World Data From the International GOSAFE Study.
    J Clin Oncol. 2024 Apr 30:JCO2400763. doi: 10.1200/JCO.24.00763.
    

    >> Share

    
    
41. HU H, Zhang J, Li Y, Wang X, et al
    Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial.
    J Clin Oncol. 2024 Apr 2:JCO2301889. doi: 10.1200/JCO.23.01889.
    

    >> Share

    
    
42. CHAVEZ-VILLA M, Ruffolo LI, Line PD, Dueland S, et al
    Emerging Role of Liver Transplantation for Unresectable Colorectal Liver Metastases.
    J Clin Oncol. 2024;42:1098-1101.
    

    >> Share

    
    March 2024
43. GALLOIS C, Shi Q, Pederson LD, Andre T, et al
    Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.
    J Clin Oncol. 2024 Mar 28:JCO2301326. doi: 10.1200/JCO.23.01326.
    

    >> Share

    
    
44. GAO Z, Zhu Z, Li K
    Immunoscore Biopsy in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy.
    J Clin Oncol. 2024;42:1088.
    

    >> Share

    
    
45. MEHTSUN WT, Gupta S
    Racial Disparities in Receipt of Guideline-Concordant Care for Early-Onset Colorectal Cancer-We Must Do Better.
    J Clin Oncol. 2024 Mar 15:JCO2302186. doi: 10.1200/JCO.23.02186.
    

    >> Share

    
    
46. DOMINGO E, Kelly C, Hay J, Sansom O, et al
    Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.
    J Clin Oncol. 2024 Mar 14:JCO2301648. doi: 10.1200/JCO.23.01648.
    

    >> Share

    
    
47. LORIA A, Ramsdale EE, Aquina CT, Cupertino P, et al
    From Clinical Trials to Practice: Anticipating and Overcoming Challenges in Implementing Watch-and-Wait for Rectal Cancer.
    J Clin Oncol. 2024;42:876-880.
    

    >> Share

    
    
48. FOKAS E, Smith JJ, Garcia-Aguilar J, Glynne-Jones R, et al
    Early Efficacy End Points in Neoadjuvant Rectal Cancer Trials: Surrogacy Revisited.
    J Clin Oncol. 2024;42:872-875.
    

    >> Share

    
    
49. BATTAGLIN F, Ou FS, Qu X, Hochster HS, et al
    HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405.
    J Clin Oncol. 2024 Mar 8:JCO2301507. doi: 10.1200/JCO.23.01507.
    

    >> Share

    
    
50. SHAH SC, Camargo MC, Lamm M, Bustamante R, et al
    Impact of Helicobacter pylori Infection and Treatment on Colorectal Cancer in a Large, Nationwide Cohort.
    J Clin Oncol. 2024 Mar 1:JCO2300703. doi: 10.1200/JCO.23.00703.
    

    >> Share

    
    February 2024
51. RAHBARI NN, Biondo S, Frago R, Feisst M, et al
    Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials.
    J Clin Oncol. 2024 Feb 27:JCO2301540. doi: 10.1200/JCO.23.01540.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share